



IPHA

THE AT- A -GLANCE INFORMATION SOURCE FOR IPHA MEMBERS

**Ronald Portman.Chairman**  
**Jonathan Sorof.Chairman-elect**  
**Joseph Flynn.Secretary**  
**Julie Ingelfinger.Liaison**

**IN THIS ISSUE:**

**IPHA Awarded Pediatric Academic Society Affiliate Status**

**NIH Funding Request for applications**

**Dr. Portman to serve on the FDA Panel**

**Update on Pediatric HTN Textbook**

**ASH Initiative**

**Recent Publications**

**Executive Committee**

Bruce Alpert  
 Bonita Falkner  
 Joseph Flynn  
 Gregory Harshfield  
 Julie Ingelfinger  
 Empar Lurbe  
 Bruce Morgenstern  
 Ronald Portman  
 Jonathan Sorof  
 Elke Wuehl

For submissions to the newsletter please contact:

Jennifer Turner at:  
 713.500.5113  
 Jennifer.L.Turner@uth.tmc.edu

PEDHTN is administrated by:

Ron Portman Mail to:  
 Ronald.Portman@uth.tmc.edu  
 & by Andrew Aronson Mail to:  
 drandrewj@triton.net

**IPHA AWARDED OFFICIAL PEDIATRIC ACADEMIC SOCIETY AFFILIATE STATUS**

Through the efforts of Chairman Ron Portman and the endorsement of the American Society of Pediatric Nephrology, IPHA has been named an official affiliate society of the PAS. Representing IPHA, Jonathan Sorof attended the PAS 2004 Planning Committee meeting in San Francisco in August to help add topics related to pediatric hypertension to the official program. We are pleased to announce that several IPHA-led initiatives have been confirmed

**Joint PAS / ASPN / IPHA Symposium**  
Implications of the Food and Drug Modernization Act (FDAMA) for the Field of Pediatric Hypertension

1.Scope of the Problem of Juvenile Hypertension: Changing Epidemiology & Measurement Technology

Speaker: Jonathan Sorof, MD  
 University of Texas-Houston Medical School

2.FDA Perspective on FDAMA: Successes, Failures, and Future Directions

Speaker: Rosemary Roberts MD  
 Food and Drug Administration

3.Recently Published Guidelines for Adult Hypertension and Their Implications for Children

Speaker: Ronald Portman, MD  
 University of Texas-Houston Medical School

4.Ethical Controversies Generated by Pediatric Antihypertensive Trials: Risks, Benefits, and Protection of Children

Speaker: Joseph T. Flynn, MD  
 Montefiore Medical Center

**PAS / IPHA Symposium**  
Update on Pediatric Hypertension

A Report on the Proceedings of a Working Group from the High Blood Pressure Education Program of the National Heart Lung and Blood Institute.

1.Definition of Hypertension with a Re-examination of the National Data on Blood Pressure in Children and Adolescents.

Speaker: Bonita Falkner, MD

2.Relationship between Cardiovascular Risk Factors and Sequelae in Hypertension Children

Speaker: Elaine Urbina, MD

**PAS/IPHA SYMPOSIUM (CONT.)**

3.Update on Therapy for Pediatric Hypertension  
 Speaker: Joseph Flynn, MD

4.Methods and Instruments for Measuring Blood Pressure in the Young

Speaker: Bruce Morgenstern, MD

In addition to these important symposia, the PAS will for the first time include "Pediatric Hypertension" as an abstract theme for submitted abstracts to the meeting. We would encourage all IPHA members to try and attend this important PAS meeting and to send their best research abstracts for presentation to the meeting.

**IPHA INVOLVEMENT IN NIH APPLICATION FOR CHRONIC KIDNEY DISEASE STUDIES**

The two applications that were submitted in response to the RFA for a longitudinal study of the effects of chronic renal failure in children will both be funded. Cardiovascular effects of CKD received a great deal of attention in both applications, and will clearly need to be incorporated into the final protocol. It is likely that several IPHA members, including Steve Daniels, Joseph Flynn, Mark Mitsnefes, Rulan Parekh, John Mahan, and Ron Portman will be working together to develop the cardiovascular component of the final protocol.

**DR. PORTMAN TO SERVE ON THE FDA PEDIATRIC ADVISORY PANEL**

Dr. Portman has been appointed by the Department of Health and Human Services to serve on the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration through June 2007 chaired by Douglas Throckmorton, MD. The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cardiovascular and renal disorders and makes appropriate recommendations to the Commissioner of Food and Drugs. Dr. Portman will participate in this process for all drugs but will focus much of his efforts on drugs for children and adolescents.

## PEDIATRIC HYPERTENSION TEXTBOOK UPDATE

The new pediatric hypertension textbook edited by Portman, Sorof, and Ingelfinger (part of the Hypertension textbook series edited by Bill White) is nearing completion and should be available for the May 2004 ASH/PAS meetings. See excerpts of the preface to the book below for a “taste” of what is to come:

“This volume begins with chapters concerning blood pressure regulation in the very young—transition from fetal life to infant circulation, the factors that regulate blood pressure in early childhood, and the chronobiology of pediatric blood pressure. We then move on to assessment of blood pressure in children. The book addresses both casual and ambulatory blood pressure measurement methodologies and norms, as well as the epidemiology of hypertension in children.

Definitions of hypertension in children, predictors of future hypertension, risk factors and special populations are discussed at length. Comprehensive chapters on both primary and secondary hypertension in children point out differences in presentation of hypertension in the pediatric population as compared to the adult population. The contributions of genetics to the understanding of hypertension are presented, as well as those events during gestation and perinatal life that may influence the development of later hypertension. Risk factors that are discussed include the influences of race and ethnicity, diet, obesity, and society. Special populations including the neonate with hypertension and the child with chronic renal failure or end stage renal disease are each discussed in a separate chapter. In those chapters, the pathophysiology insofar as is known is also considered.

This text finishes with a section that focuses on evaluation and management of pediatric hypertension. Suggestions for evaluation are presented, and both non-pharmacologic and pharmacologic therapy are discussed at length. The 1997 Food and Drug Administration Modernization Act, which offers extension of market exclusivity in return for approved clinical trials of medications with pediatric indication, has had a major impact on the conduct of pediatric antihypertensive medication trials. The current status of such pediatric antihypertensive trials are presented.”

## AMERICAN SOCIETY OF HYPERTENSION INITIATIVE

As mentioned in previous newsletters, Bonnie Falkner has helped organize a Working Group for the High Blood Pressure Education Program of the National Heart Lung and Blood Institute. This meeting is due to take place in December, with the consensus statements ready for dissemination by the Spring of 2004. Ronald Portman is in discussion with the current president of ASH to have information presented as a plenary session at the spring meeting. This new Working Group report would be the pediatric equivalent of the recent JNC-VII report. The response from ASH has thus far been very positive. More updates to follow.

## RECENT ARTICLES BY IPHA MEMBERS

- Mitsnefes MM, Khoury PR, McEnery PT. Early posttransplantation hypertension and poor long-term renal allograft survival in pediatric patients. *J Pediatr* 2003; 143:98-103.
- Mitsnefes MM, Portman RJ. Ambulatory blood pressure monitoring in pediatric renal transplantation. *Pediatr Transplant* 2003; 7:86-92.
- Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. *Circulation* 2003; 107:1562-1566.
- Patzer L, Seeman T, Luck C, Wuehl E, Janda J, Misselwitz J. Day and night-time blood pressure elevations in children with higher grades of renal scarring. *J Pediatr* 2003;142:117-22.
- Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matalo TK, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. *Pediatr Nephrol* 2003; 18:548-553.
- Barbeau P, Litaker MS, Harshfield GA. Impaired pressure natriuresis in obese youths. *Obes.Res.* 2003; 11:745-751.
- Snieder H, Harshfield GA, Treiber FA. Heritability of blood pressure and hemodynamics in African- and European-American youth. *Hypertension* 2003; 41:1196-1201.
- Dinavahi R, Cossrow N, Kushner H, Falkner B. Plasma homocysteine concentration and blood pressure in young adult African Americans. *Am J Hypertens* 2003; 16:767-770.
- Butani L, Morgenstern BZ. Are pitfalls of oxillometric blood pressure measurements preventable in children? *Pediatr Nephrol* 2003; 18:313-318.
- Blumer JL, Daniels SR, Dreyer WJ, Batisky D, Walson PD, Roman D, et al. Pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment. *J Clin Pharmacol.* 2003; 43:128-132.
- Sorof JM, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. *Pediatrics* 2003; 111:61-66.
- Sorof JM, Alexandrov AV, Garami Z, Turner JL, Grafe RE, Lai D, et al. Carotid ultrasonography for detection of vascular abnormalities in hypertensive children. *Pediatr Nephrol* 2003 (In press)
- Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. *Pediatrics* (In press)
- Flynn JT. Recognizing and managing the hypertensive child. *Contemporary Pediatrics* 2003; 20:38-60.
- Flynn JT. Successes and shortcomings of the FDA Modernization Act (editorial). *American Journal of Hypertension* (In press).
- Flynn JT. Ethics of Placebo Use in Pediatric Clinical Trials: The Case of Antihypertensive Drug Studies *Hypertension* (In press)